Nasal Packing, Dexmedetomidine, Turbinate
Conditions
Brief summary
Comparing of nasal packing DEX and IV DEX for controlling the intraoperative bleeding after turbinate surgery.
Detailed description
Dexmedetomidine (DEX) is a highly selective α2 adreno-receptor agonist with higher affinity to a2 adreno-receptor than clonidine, and this makes DEX primarily sedative and anxiolytic. The elimination half-life of DEX (t1/2b) is 2 h and the redistribution half-life (t1/2a) is 6 min, and this short half-life makes it an ideal drug for intravenous titration. Potentially desirable effects include decreased requirements for other anesthetics and analgesics.
Interventions
DRUGNasal packing Dexmedetomidine
patients will receive nasal packing Dexmedetomidine (1.5 μg/kg intranasal dexmedetomidine diluted with saline) and Intravenous infusion saline.
patients will receive 0.5 μg/kg bolus over 10 min then 0.1- 0.4 μg/kg Intravenous infusion Dexmedetomidine and nasal packing with saline.
Sponsors
Kafrelsheikh University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Age 18 to 65 years * Both sexes * American Society of Anesthesiologists (ASA) physical status classification I or II. * Undergo turbinate surgery
Exclusion criteria
* Patients with a body mass index \> 30 kg/m2 existing or recent significant disease. * Contraindications to the use of dexmedetomidine . * History or presence of a significant disease significant cardiovascular disease risk factors. * Significant coronary artery disease or any known genetic predisposition. * History of any kind of drug allergy, * Drug abuse. * Clinically significant abnormal findings in physical examination, electrocardiographic (ECG) or laboratory screening. * Known systemic disease requiring the use of anticoagulants, * Patients with a history of previous turbinate surgery.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Amount of intraoperative blood loss | Intraoperative up to 6hours | Measuring the volume of suctioned blood in graduated columns, which will contain an anticoagulant to prevent coagulation and clotting and weighing gauze sponges. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain score | 24 hours postoperative | Visual analogue scale (VAS) (0, no discomfort and no pain; 10, a high level of discomfort and maximum pain) |
| Quality of intraoperative surgical field | Intraoperative up to 6hours | Quality of intraoperative surgical field during after turbinate surgery will be evaluated by the surgeons by rating the amount of bleeding according to a 6-point scale by Formmer's scores of surgical field quality (0= no bleeding; 1= bleeding, so mild it was not even a surgical nuisance; 2= moderate bleeding, a nuisance but without interference; 3= moderate bleeding that moderately compromised surgical; 4= bleeding, heavy but controllable, that significantly interfered; 5= massive uncontrollable bleeding) |
| Patient's general satisfaction | 24 hours postoperative | Patients' satisfaction will be measured immediately postoperative and using a five-point Likert scale consisting of very dissatisfied, dissatisfied, unsure, satisfied, and very satisfied. |
Countries
Egypt
Outcome results
None listed